<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for John Lechleiter]]></title>
<description><![CDATA[Watch breaking news videos and read news updates about John Lechleiter on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=127219"/>
<item>
<title><![CDATA[Lilly CEO to undergo surgery, CFO Rice to become interim CEO]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/06/lilly-ceo-to-undergo-surgery-cfo-rice-to-become-interim-ceo/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/06/lilly-ceo-to-undergo-surgery-cfo-rice-to-become-interim-ceo/</guid>
<pubDate><![CDATA[Mon, 06 May 2013 17:44:28 EDT]]></pubDate>
<description><![CDATA[Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the drugmaker said on Monday.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/05/06/2013-05-06T214428Z_1_CBRE9451OEA00_3_APEC.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[Lilly CEO Lechleiter to undergo surgery for dilated aorta]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/06/lilly-ceo-lechleiter-to-undergo-surgery-for-dilated-aorta/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/06/lilly-ceo-lechleiter-to-undergo-surgery-for-dilated-aorta/</guid>
<pubDate><![CDATA[Mon, 06 May 2013 17:27:16 EDT]]></pubDate>
<description><![CDATA[Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/05/06/2013-05-06T212716Z_1_CBRE9451NLI00_3_HEALTH-SUMMIT.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[Lilly's 4Q Profit Falls on Generic Competition]]></title>
<link><![CDATA[http://www.foxbusiness.com/personal-finance/2013/01/29/generics-hurt-lilly-4q-earnings-results/?]]></link>
<guid>http://www.foxbusiness.com/personal-finance/2013/01/29/generics-hurt-lilly-4q-earnings-results/</guid>
<pubDate><![CDATA[Tue, 29 Jan 2013 10:06:11 EST]]></pubDate>
<description><![CDATA[The U.S. drugmaker saw a drop in fourth-quarter profit fell as competition from generic drugs impacted revenue. ]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/video/012913_Fb_lilly.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Eli Lilly Forecasts Stronger 2013]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2013/01/04/eli-lilly-expects-2013-earnings-to-rise/?]]></link>
<guid>http://www.foxbusiness.com/industries/2013/01/04/eli-lilly-expects-2013-earnings-to-rise/</guid>
<pubDate><![CDATA[Fri, 04 Jan 2013 09:52:15 EST]]></pubDate>
<description><![CDATA[The pharmaceutical maker sees 2013 earnings rising to $3.75 to $3.90 a share and topping Wall Street estimates. ]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/news/Mosaic-logo.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Eli Lilly to Expand Insulin-Manufacturing Facilities]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/30/eli-lilly-to-expand-insulin-manufacturing-facilities/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/30/eli-lilly-to-expand-insulin-manufacturing-facilities/</guid>
<pubDate><![CDATA[Tue, 30 Oct 2012 12:54:23 EDT]]></pubDate>
<description><![CDATA[Eli Lilly & Co. (LLY) plans to expand its Indianapolis insulin-manufacturing facilities in a multimillion-dollar investment to meet growing demand in the U.S.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly Alzheimer's Drug Fails in Late-Stage Trial]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/08/24/eli-lilly-alzheimer-drug-fails-in-late-stage-trials/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/08/24/eli-lilly-alzheimer-drug-fails-in-late-stage-trials/</guid>
<pubDate><![CDATA[Fri, 24 Aug 2012 09:32:20 EDT]]></pubDate>
<description><![CDATA[Eli Lilly said its experimental treatment for Alzheimer’s failed in a late-stage trial, but optimistic commentary sent shares jumping.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/industries/health-care/BMS-test-tubes.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Lilly's Alzheimer Shows Promise; Misses Goals]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/08/24/lilly-alzheimer-shows-promise-misses-goals/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/08/24/lilly-alzheimer-shows-promise-misses-goals/</guid>
<pubDate><![CDATA[Fri, 24 Aug 2012 08:35:05 EDT]]></pubDate>
<description><![CDATA[Eli Lilly & Co. (LLY) said solanezumab, a highly anticipated potential treatment for Alzheimer's disease, failed to reach its set goals in either of two Phase 3 studies, although pooled data from both studies showed signs of the drug slowing cognitive decline overall in patients with mild-to-moderate cases.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Bristol-Myers, Lilly Remain Optimistic Despite Patent Woes]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/07/25/bristol-myers-lilly-remain-optimistic-despite-patent-woes/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/07/25/bristol-myers-lilly-remain-optimistic-despite-patent-woes/</guid>
<pubDate><![CDATA[Wed, 25 Jul 2012 16:04:02 EDT]]></pubDate>
<description><![CDATA[Two major U.S. drug companies took big hits to quarterly profits and sales because patent expirations for their top products cleared the way for generic competition.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Bristol-Myers, Lilly 2Q Sales Drop Amid Patent Expirations]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/07/25/bristol-myers-lilly-post-2q-sales-declines-as-blockbusters-lose-exclusivity/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/07/25/bristol-myers-lilly-post-2q-sales-declines-as-blockbusters-lose-exclusivity/</guid>
<pubDate><![CDATA[Wed, 25 Jul 2012 10:34:16 EDT]]></pubDate>
<description><![CDATA[Bristol-Myers Squibb and Eli Lilly posted weaker quarterly earnings and sales on Wednesday as they struggled to stem losses from patent expirations.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly 2nd-Quarter Net Falls 23% as Zyprexa Sales Drop; Raises Year View]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/07/25/eli-lilly-2nd-quarter-net-falls-23-as-zyprexa-sales-drop-raises-year-view/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/07/25/eli-lilly-2nd-quarter-net-falls-23-as-zyprexa-sales-drop-raises-year-view/</guid>
<pubDate><![CDATA[Wed, 25 Jul 2012 09:12:30 EDT]]></pubDate>
<description><![CDATA[Eli Lilly & Co. (LLY) said its second-quarter profit declined 23%, as the drug maker continues to feel the effects of the recent patent expiration for antipsychotic Zyprexa.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly to Complete Decade-Old Buyback Program]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/06/19/eli-lilly-to-complete-12-year-old-buyback-program/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/06/19/eli-lilly-to-complete-12-year-old-buyback-program/</guid>
<pubDate><![CDATA[Tue, 19 Jun 2012 11:04:26 EDT]]></pubDate>
<description><![CDATA[Shares of Eli Lilly touched a new high Tuesday morning after the company said it would resume share buybacks after breaking for half a decade. ]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/nook.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Lilly 1Q Profit Narrows, But Beats on Cymbalta Demand]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/04/25/lilly-1q-results-beat-street/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/04/25/lilly-1q-results-beat-street/</guid>
<pubDate><![CDATA[Wed, 25 Apr 2012 09:13:27 EDT]]></pubDate>
<description><![CDATA[Eli Lilly narrowed its first-quarter profit but still beat Wall Street's expectations on strong Cymbalta sales and price increases.  ]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Drug Executives Tout R&D Spending As Industry Hits Patent Cliff]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/04/12/drug-executives-tout-rd-spending-as-industry-hits-patent-cliff/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/04/12/drug-executives-tout-rd-spending-as-industry-hits-patent-cliff/</guid>
<pubDate><![CDATA[Thu, 12 Apr 2012 15:21:01 EDT]]></pubDate>
<description><![CDATA[Drug-industry executives touted on Thursday the investments they are making to discover new products in the face of a so-called patent cliff that will dramatically cut revenue over the next several years and has caused some companies to scale back research budgets.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly CEO on Drug Innovation, Corporate Taxes]]></title>
<link><![CDATA[http://video.foxbusiness.com/v/1466896733001/eli-lilly-ceo-on-drug-innovation-corporate-taxes/?]]></link>
<guid>http://video.foxbusiness.com/v/1466896733001/eli-lilly-ceo-on-drug-innovation-corporate-taxes/</guid>
<pubDate><![CDATA[Wed, 22 Feb 2012 17:18:03 EST]]></pubDate>
<description><![CDATA[Eli Lilly CEO John Lechleiter on new drugs in the company’s pipeline and Obama’s corporate tax proposal.]]></description>
<media:thumbnail>http://video.foxbusiness.com/thumbnails/022212/640/360/022212_atb_lechleiter.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Patent Losses Hit Pfizer, Lilly As Both Await Alzheimer's Drug Data]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/31/patent-losses-hit-pfizer-lilly-as-both-await-alzheimers-drug-data/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/31/patent-losses-hit-pfizer-lilly-as-both-await-alzheimers-drug-data/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 14:07:02 EST]]></pubDate>
<description><![CDATA[Drug makers Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) fell off the so-called "patent cliff," each reporting declines in fourth-quarter profits due to new generic competition for top-selling drugs.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Lilly 4Q Profit Slips on Generics, But Still Beats]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/01/31/lilly-4q-profit-plunges-but-beats-estimates/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/01/31/lilly-4q-profit-plunges-but-beats-estimates/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 10:00:02 EST]]></pubDate>
<description><![CDATA[Eli Lilly said its fourth-quarter profit dropped 27% on loss of patent exclusivity of top-selling Zyprexa.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Lilly 4Q Net Drops 27% As Zyprexa Sales Drop 44%]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/31/lilly-4q-net-drops-27-as-zyprexa-sales-drop-44/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/31/lilly-4q-net-drops-27-as-zyprexa-sales-drop-44/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 08:28:13 EST]]></pubDate>
<description><![CDATA[Eli Lilly & Co. (LLY) reported a 27% decline in fourth-quarter profit, as sales of antipsychotic Zyprexa took a big hit from new generic competition.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly Predicts Profit Plunge in '12]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/01/05/eli-lilly-predicts-sharp-drop-in-profit-in-2012-as-patents-expire/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/01/05/eli-lilly-predicts-sharp-drop-in-profit-in-2012-as-patents-expire/</guid>
<pubDate><![CDATA[Thu, 05 Jan 2012 11:14:40 EST]]></pubDate>
<description><![CDATA[Eli Lilly on Thursday predicted a sharp drop in fiscal 2012 results when a number of its largest products are expected to lose patent exclusivity.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Eli Lilly Q3 Net Profit Drops 5%; Sales Rise 9%]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2011/10/20/eli-lilly-q3-net-profit-drops-5-sales-rise/?]]></link>
<guid>http://www.foxbusiness.com/markets/2011/10/20/eli-lilly-q3-net-profit-drops-5-sales-rise/</guid>
<pubDate><![CDATA[Thu, 20 Oct 2011 10:07:54 EDT]]></pubDate>
<description><![CDATA[Eli Lilly disclosed a 5% decrease in third-quarter profits amid higher costs on Thursday, but the big drug maker’s non-GAAP earnings met Wall Street’s expectations.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[President Obama Signs Patent Reform Bill Into Law]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2011/09/16/obama-signs-patent-reform-bill/?]]></link>
<guid>http://www.foxbusiness.com/industries/2011/09/16/obama-signs-patent-reform-bill/</guid>
<pubDate><![CDATA[Fri, 16 Sep 2011 13:18:19 EDT]]></pubDate>
<description><![CDATA[President Obama signed into law a patent overhaul bill aimed at spurring innovation and hiring by reducing frivolous lawsuits.]]></description>
<media:thumbnail>http://www.foxbusiness.com/static/managed/img/Obama-signs-American-Invents-Act.jpg</media:thumbnail>
</item>
</channel>
</rss>
